Annexin Pharmaceuticals AB and CDMO Biovian Oy released the First-In-Class ANXV drug candidate for clinical trials. Following a clinical study in healthy subjects, clinical trials with the drug will target retinal vein occlusion, a condition …
Affibody AB, a Swedish biotech company focused on developing next-generation biopharmaceuticals has selected Biovian Oy, the leading Nordic One-Stop-Shop CDMO for biopharmaceuticals as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The …
